Hiroko Ikeda

3.6k total citations · 1 hit paper
57 papers, 2.4k citations indexed

About

Hiroko Ikeda is a scholar working on Psychiatry and Mental health, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Hiroko Ikeda has authored 57 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Psychiatry and Mental health, 14 papers in Molecular Biology and 13 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Hiroko Ikeda's work include Epilepsy research and treatment (17 papers), Genetics and Neurodevelopmental Disorders (11 papers) and Pharmacological Effects and Toxicity Studies (9 papers). Hiroko Ikeda is often cited by papers focused on Epilepsy research and treatment (17 papers), Genetics and Neurodevelopmental Disorders (11 papers) and Pharmacological Effects and Toxicity Studies (9 papers). Hiroko Ikeda collaborates with scholars based in Japan, United States and Italy. Hiroko Ikeda's co-authors include Yukitoshi Takahashi, Nami Goto‐Yamamoto, Kazuya Koyama, Puspa Raj Poudel, Masaaki Muramatsu, Yoshiro Saito, Michiko Aihara, Nahoko Kaniwa, Jacqueline A. French and Zühal Yapıcı and has published in prestigious journals such as The Lancet, Gastroenterology and Neurology.

In The Last Decade

Hiroko Ikeda

54 papers receiving 2.3k citations

Hit Papers

Adjunctive everolimus therapy for treatment-resistant foc... 2016 2026 2019 2022 2016 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study
    2016 500 citations Jacqueline A. French, John A. Lawson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroko Ikeda Japan 21 659 593 480 447 417 57 2.4k
F. Nantel Canada 27 453 0.7× 1.2k 2.0× 85 0.2× 673 1.5× 345 0.8× 77 2.7k
Céline Martel Canada 37 133 0.2× 794 1.3× 443 0.9× 128 0.3× 2.0k 4.7× 102 4.1k
Tomo‐o Ishikawa United States 24 386 0.6× 1.1k 1.8× 145 0.3× 143 0.3× 355 0.9× 43 2.3k
Maria Grazia Tozzi Italy 26 123 0.2× 1.5k 2.5× 66 0.1× 133 0.3× 230 0.6× 106 2.4k
Guimin Gao United States 22 117 0.2× 849 1.4× 82 0.2× 179 0.4× 610 1.5× 76 1.7k
S. Rastogi United States 25 61 0.1× 967 1.6× 122 0.3× 168 0.4× 97 0.2× 54 2.2k
Sebastian Brandhorst United States 24 91 0.1× 1.2k 2.0× 64 0.1× 2.4k 5.3× 289 0.7× 33 3.8k
John N. Snouwaert United States 22 327 0.5× 1.3k 2.2× 36 0.1× 375 0.8× 399 1.0× 40 2.8k
Ilan Elson‐Schwab United States 9 103 0.2× 603 1.0× 62 0.1× 459 1.0× 80 0.2× 9 1.6k
Kenneth N. Maclean United States 32 45 0.1× 1.2k 2.0× 36 0.1× 425 1.0× 592 1.4× 74 3.2k

Countries citing papers authored by Hiroko Ikeda

Since Specialization
Citations

This map shows the geographic impact of Hiroko Ikeda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroko Ikeda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroko Ikeda more than expected).

Fields of papers citing papers by Hiroko Ikeda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroko Ikeda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroko Ikeda. The network helps show where Hiroko Ikeda may publish in the future.

Co-authorship network of co-authors of Hiroko Ikeda

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroko Ikeda. A scholar is included among the top collaborators of Hiroko Ikeda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroko Ikeda. Hiroko Ikeda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nishida, Takuji, Hitoshi Ikeda, Hiroko Ikeda, et al.. (2025). Long‐term seizure and psychosocial outcomes of patients with ring chromosome 20 syndrome: A cohort study of 47 cases. Epilepsia. 66(7). 2444–2453. 1 indexed citations
2.
Franz, David Neal, John A. Lawson, Zühal Yapıcı, et al.. (2021). Adjunctive everolimus therapy for tuberous sclerosis complex‐associated refractory seizures: Results from the postextension phase of EXIST‐3. Epilepsia. 62(12). 3029–3041. 23 indexed citations
3.
Yamamoto, Ayako, Yoshiaki Saito, Yoshitaka Oyama, et al.. (2020). Effect of total callosotomy on KCNQ2-related intractable epilepsy. Brain and Development. 42(8). 612–616. 3 indexed citations
4.
Takahashi, Yukitoshi, Asako Horino, Takayoshi Koike, et al.. (2020). Methylprednisolone pulse therapy in 31 patients with refractory epilepsy: A single-center retrospective analysis. Epilepsy & Behavior. 109. 107116–107116. 11 indexed citations
5.
Takahashi, Yukitoshi, Tokito Yamaguchi, Asako Horino, et al.. (2019). Quinidine therapy and therapeutic drug monitoring in four patients with KCNT1 mutations. Epileptic Disorders. 21(1). 48–54. 31 indexed citations
6.
Mizuguchi, Masashi, Hiroko Ikeda, Kuriko Kagitani‐Shimono, et al.. (2018). Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan. Brain and Development. 41(1). 1–10. 57 indexed citations
7.
8.
Takahashi, Yukitoshi, Asako Horino, Takayoshi Koike, et al.. (2018). Chronic dysfunction of blood-brain barrier in patients with post-encephalitic/encephalopathic epilepsy. Seizure. 63. 85–90. 8 indexed citations
9.
Curatolo, Paolo, David Neal Franz, John A. Lawson, et al.. (2018). Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. The Lancet Child & Adolescent Health. 2(7). 495–504. 74 indexed citations
10.
Mutoh, Hiroki, Mitsuhiro Kato, Tenpei Akita, et al.. (2018). Biallelic Variants in CNPY3, Encoding an Endoplasmic Reticulum Chaperone, Cause Early-Onset Epileptic Encephalopathy. The American Journal of Human Genetics. 102(2). 321–329. 17 indexed citations
11.
Takayama, Rumiko, Katsumi Imai, Hiroko Ikeda, et al.. (2018). Successful hemispherotomy in two refractory epilepsy patients with cerebral hemiatrophy and contralateral EEG abnormalities. Brain and Development. 40(7). 601–606. 3 indexed citations
12.
Takahashi, Yukitoshi, Asako Horino, Takayoshi Koike, et al.. (2016). A case of early onset epileptic encephalopathy with de novo mutation in SLC35A2: Clinical features and treatment for epilepsy. Brain and Development. 39(3). 256–260. 25 indexed citations
13.
Yamamoto, Toshiyuki, Keiko Shimojima, Yukiko Mogami, et al.. (2015). Recurrent occurrences of CDKL5 mutations in patients with epileptic encephalopathy. Human Genome Variation. 2(1). 15042–15042. 6 indexed citations
14.
Ikeda, Hiroko, et al.. (2012). Clinical characteristics of epilepsy in patients with moyamoya disease. Nosotchu. 34(3). 140–146.
15.
Liang, Jao‐Shwann, Keiko Shimojima, Rumiko Takayama, et al.. (2011). CDKL5 alterations lead to early epileptic encephalopathy in both genders. Epilepsia. 52(10). 1835–1842. 58 indexed citations
16.
17.
Takahashi, Hiroka, Yukitoshi Takahashi, Jun Mine, et al.. (2010). [Effectiveness of topiramate in eleven patients with Dravet syndrome].. PubMed. 42(4). 273–6. 4 indexed citations
18.
Oguni, Hirokazu, Jao‐Shwann Liang, Hiroko Ikeda, et al.. (2010). STXBP1 mutations cause not only Ohtahara syndrome but also West syndrome—Result of Japanese cohort study. Epilepsia. 51(12). 2449–2452. 79 indexed citations
19.
Kaniwa, Nahoko, Yoshiro Saito, Michiko Aihara, et al.. (2010). HLA‐B*1511 is a risk factor for carbamazepine‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia. 51(12). 2461–2465. 168 indexed citations
20.
Ikeda, Hiroko, Hisashi Kawawaki, & Kiyotaka Tomiwa. (2003). Usefulness of Ethyl Loflazepate in Landau-Kleffner Syndrome. Journal of the Japan Epilepsy Society. 21(2). 185–191. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F. Nantel Breakdown of academic impact, for papers by Céline Martel Breakdown of academic impact, for papers by Tomo‐o Ishikawa Breakdown of academic impact, for papers by Maria Grazia Tozzi Breakdown of academic impact, for papers by Guimin Gao Breakdown of academic impact, for papers by S. Rastogi Breakdown of academic impact, for papers by Sebastian Brandhorst Breakdown of academic impact, for papers by John N. Snouwaert Breakdown of academic impact, for papers by Ilan Elson‐Schwab Breakdown of academic impact, for papers by Kenneth N. Maclean
Rankless by CCL
2026